Now showing items 1199-1218 of 3147

    • Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. 

      Zafeiriou, Z; Bianchini, D; Chandler, R; Rescigno, P; Yuan, W; Carreira, S; Barrero, M; Petremolo, A; Miranda, S; Riisnaes, R; Rodrigues, DN; Gurel, B; Sumanasuriya, S; Paschalis, A; Sharp, A; Mateo, J; Tunariu, N; Chinnaiyan, AM; Pritchard, CC; Kelly, K; de Bono, JS (2019-01)
      Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, ...
    • A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. 

      Scott, RA; Freitag, DF; Li, L; Chu, AY; Surendran, P; Young, R; Grarup, N; Stancáková, A; Chen, Y; Varga, TV; Yaghootkar, H; Luan, J; Zhao, JH; Willems, SM; Wessel, J; Wang, S; Maruthur, N; Michailidou, K; Pirie, A; van der Lee, SJ; Gillson, C; Al Olama, AA; Amouyel, P; Arriola, L; Arveiler, D; Aviles-Olmos, I; Balkau, B; Barricarte, A; Barroso, I; Garcia, SB; Bis, JC; Blankenberg, S; Boehnke, M; Boeing, H; Boerwinkle, E; Borecki, IB; Bork-Jensen, J; Bowden, S; Caldas, C; Caslake, M; Cupples, LA; Cruchaga, C; Czajkowski, J; den Hoed, M; Dunn, JA; Earl, HM; Ehret, GB; Ferrannini, E; Ferrieres, J; Foltynie, T; Ford, I; Forouhi, NG; Gianfagna, F; Gonzalez, C; Grioni, S; Hiller, L; Jansson, JH; Jørgensen, ME; Jukema, JW; Kaaks, R; Kee, F; Kerrison, ND; Key, TJ; Kontto, J; Kote-Jarai, Z; Kraja, AT; Kuulasmaa, K; Kuusisto, J; Linneberg, A; Liu, C; Marenne, G; Mohlke, KL; Morris, AP; Muir, K; Müller-Nurasyid, M; Munroe, PB; Navarro, C; Nielsen, SF; Nilsson, PM; Nordestgaard, BG; Packard, CJ; Palli, D; Panico, S; Peloso, GM; Perola, M; Peters, A; Poole, CJ; Quirós, JR; Rolandsson, O; Sacerdote, C; Salomaa, V; Sánchez, MJ; Sattar, N; Sharp, SJ; Sims, R; Slimani, N; Smith, JA; Thompson, DJ; Trompet, S; Tumino, R; van der A, DL; van der Schouw, YT; Virtamo, J; Walker, M; Walter, K; Abraham, JE; Amundadottir, LT; Aponte, JL; Butterworth, AS; Dupuis, J; Easton, DF; Eeles, RA; Erdmann, J; Franks, PW; Frayling, TM; Hansen, T; Howson, JM; Jørgensen, T; Kooner, J; Laakso, M; Langenberg, C; McCarthy, MI; Pankow, JS; Pedersen, O; Riboli, E; Rotter, JI; Saleheen, D; Samani, NJ; Schunkert, H; Vollenweider, P; O'Rahilly, S; Deloukas, P; Danesh, J; Goodarzi, MO; Kathiresan, S; Meigs, JB; Ehm, MG; Wareham, NJ; Waterworth, DM (2016-06)
      Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to guide development of antidiabetic ...
    • Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients 

      Stratton, M (2010-06)
      Distinct molecular subtypes of breast carcinomas have been identified, but translation into clinical use has been limited. We have developed two platform-independent algorithms to explore genomic architectural distortion ...
    • A genomic atlas of human adrenal and gonad development. 

      Del Valle, I; Buonocore, F; Duncan, AJ; Lin, L; Barenco, M; Parnaik, R; Shah, S; Hubank, M; Gerrelli, D; Achermann, JC (2017-04-07)
      BACKGROUND: In humans, the adrenal glands and gonads undergo distinct biological events between 6-10 weeks post conception (wpc), such as testis determination, the onset of steroidogenesis and primordial germ cell development. ...
    • Genomic Classification and Prognosis in Acute Myeloid Leukemia. 

      Papaemmanuil, E; Gerstung, M; Bullinger, L; Gaidzik, VI; Paschka, P; Roberts, ND; Potter, NE; Heuser, M; Thol, F; Bolli, N; Gundem, G; Van Loo, P; Martincorena, I; Ganly, P; Mudie, L; McLaren, S; O'Meara, S; Raine, K; Jones, DR; Teague, JW; Butler, AP; Greaves, MF; Ganser, A; Döhner, K; Schlenk, RF; Döhner, H; Campbell, PJ (2016-06)
      Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical ...
    • Genomic gain and over expression of CCL2 correlate with vascular invasion in stage I non-seminomatous testicular germ-cell tumours. 

      Gilbert, DC; Chandler, I; Summersgill, B; McIntyre, A; Missiaglia, E; Goddard, NC; Huddart, RA; Shipley, J (2011-08)
      Testicular germ-cell tumours (TGCT) are the most frequent solid tumour to affect young Caucasian adult males and have increased in incidence over recent decades. In clinical stage I non-seminomas, (NSGCT) histological ...
    • Genomic instability and the selection of treatments for cancer. 

      Martin, SA; Hewish, M; Lord, CJ; Ashworth, A (2010-01)
      A critical link exists between DNA mutation and chromosomal rearrangements (genomic instability) and cancer development. This genomic instability can manifest itself as small changes at the nucleotide level or as gross ...
    • Genomic instability and TP53 genomic alterations associate with poor anti-proliferative response and intrinsic resistance to aromatase inhibitor treatment 

      Schuster, E; Gellert, P; Segal, C; Lopez-Knowles, E; Buus, R; Cheang, M; Morden, J; Robertson, J; Bliss, J; Smith, I; Dowsett, M
    • The genomic landscape of plasma cells in systemic light chain amyloidosis. 

      Boyle, EM; Ashby, C; Wardell, CP; Rowczenio, D; Sachchithanantham, S; Wang, Y; Johnson, SK; Bauer, MA; Weinhold, N; Kaiser, MF; Johnson, DC; Jones, JR; Pawlyn, C; Proszek, P; Schinke, C; Facon, T; Dumontet, C; Davies, FE; Morgan, GJ; Walker, BA; Wechalekar, AD (2018-12-27)
    • The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. 

      Litchfield, K; Levy, M; Huddart, RA; Shipley, J; Turnbull, C (2016-07)
      The genomic landscape of testicular germ cell tumour (TGCT) can be summarized using four overarching hypotheses. Firstly, TGCT risk is dominated by inherited genetic factors, which determine nearly half of all disease risk ...
    • Genomic loss of heterozygosity and survival in the REAL3 trial. 

      Smyth, EC; Cafferkey, C; Loehr, A; Waddell, T; Begum, R; Peckitt, C; Harding, TC; Nguyen, M; Okines, AF; Raponi, M; Rao, S; Watkins, D; Starling, N; Middleton, GW; Wadsley, J; Mansoor, W; Crosby, T; Wotherspoon, A; Chau, I; Cunningham, D (2018-11-30)
      Background: Homologous recombination deficiency (HRD) measured using a genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib in ovarian cancer. We hypothesized that some oesophagogastric cancers ...
    • Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). 

      Barry, GS; Cheang, MC; Chang, HL; Kennecke, HF (2016-04)
      A prospective study was conducted to identify biomarkers associated with resistance to panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Patients with previously treated, codon 12/13 KRAS wt, ...
    • GENOMIC MEDICINE Genomics and the Continuum of Cancer Care 

      Stratton, M (MASSACHUSETTS MEDICAL SOC, 2011-01)
    • Genomics, bio specimens, and other biological data: Current status and future directions. 

      Rosenstein, BS; Rao, A; Moran, JM; Spratt, DE; Mendonca, MS; Al-Lazikani, B; Mayo, CS; Speers, C (2018-10)
    • Genotoxicity of human breast milk from different countries 

      Martin, FL; Cole, KJ; Weaver, G; Hong, GS; Lam, BC; Balaram, P; Grover, PL; Phillips, DH (OXFORD UNIV PRESS, 2001-09)
      Dietary and/or environmental factors appear to play a key role in the international variations that exist in breast cancer incidence. The genotoxicity of breast milk extracts is being examined as a possible indicator of ...
    • Genotoxins and the initiation of sporadic breast cancer 

      Martin, FL (2001-03)
      Breast cancer is the most frequently diagnosed female malignancy world-wide. The aetiology of the majority of cases remains obscure and the only genotoxin as yet known to initiate breast cancer is ionizing radiation, High ...
    • Geometric and dosimetric evaluation of the differences between rigid and deformable registration to assess interfraction motion during pelvic radiotherapy 

      White, I; McQuaid, D; McNair, H; Dunlop, A; Court, S; Hopkins, N; Thomas, K; Dearnaley, D; Bhide, S; Lalondrelle, S (Elsevier BV, 2019-03-29)
    • Geometric and dosimetric evaluations of atlas-based segmentation methods of MR images in the head and neck region. 

      Kieselmann, JP; Kamerling, CP; Burgos, N; Menten, MJ; Fuller, CD; Nill, S; Cardoso, MJ; Oelfke, U (2018-07-11)
      Owing to its excellent soft-tissue contrast, magnetic resonance (MR) imaging has found an increased application in radiation therapy (RT). By harnessing these properties for treatment planning, automated segmentation methods ...
    • Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. 

      Copson, ER; Maishman, TC; Tapper, WJ; Cutress, RI; Greville-Heygate, S; Altman, DG; Eccles, B; Gerty, S; Durcan, LT; Jones, L; Evans, DG; Thompson, AM; Pharoah, P; Easton, DF; Dunning, AM; Hanby, A; Lakhani, S; Eeles, R; Gilbert, FJ; Hamed, H; Hodgson, S; Simmonds, P; Stanton, L; Eccles, DM (2018-02)
      BACKGROUND: Retrospective studies provide conflicting interpretations of the effect of inherited genetic factors on the prognosis of patients with breast cancer. The primary aim of this study was to determine the effect ...
    • Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. 

      Leongamornlert, DA; Saunders, EJ; Wakerell, S; Whitmore, I; Dadaev, T; Cieza-Borrella, C; Benafif, S; Brook, MN; Donovan, JL; Hamdy, FC; Neal, DE; Muir, K; Govindasami, K; Conti, DV; Kote-Jarai, Z; Eeles, RA (2019-02-15)
      BACKGROUND: Rare germline mutations in DNA repair genes are associated with prostate cancer (PCa) predisposition and prognosis. OBJECTIVE: To quantify the frequency of germline DNA repair gene mutations in UK PCa cases and ...